SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 424B3 - Prospectus [Rule 424(b)(3)]:
SEC Accession No. 0001493152-21-029898
Filing Date
2021-11-26
Accepted
2021-11-26 06:03:31
Documents
7

Document Format Files

Seq Description Document Type Size
1 form-424b3.htm 424B3 2340275
2 form-424b3.jpg GRAPHIC 7145
3 form-424b3_001.jpg GRAPHIC 131547
4 form-424b3_002.jpg GRAPHIC 143949
5 form-424b3_003.jpg GRAPHIC 145784
6 form-424b3_005.jpg GRAPHIC 1823
7 form-424b3_004.jpg GRAPHIC 2516
  Complete submission text file 0001493152-21-029898.txt   2938202
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 424B3 | Act: 33 | File No.: 333-234292 | Film No.: 211449057
SIC: 2834 Pharmaceutical Preparations